Brief: Pharming Group Says Provides Update On Ongoing Regulatory Review Of Leniolisib For Treatment Of APDS In EU

Pharming

30/05/2024 21:47

May 30 (Reuters) - Pharming Group NV  PHAR.AS :
    * HAS ALREADY INITIATED MANUFACTURING ACTIVITIES REQUESTED
BY
CHMP, WHICH IT PLANS TO COMPLETE PRIOR TO THIS DEADLINE.
    * PHARMING GROUP - CHMP REQUESTED THAT THIS WORK BE
COMPLETED
PRE-APPROVAL AND HAS GRANTED PHARMING AN EXTENSION TO JANUARY
2026 TO SUBMIT A RESPONSE
    * MAINTAINING ITS PREVIOUSLY PROVIDED 2024 TOTAL REVENUE
GUIDANCE
    * PHARMING GROUP PROVIDES UPDATE ON ONGOING REGULATORY
REVIEW OF
LENIOLISIB FOR TREATMENT OF APDS IN EUROPEAN UNION

Source text for Eikon:  ID:nGNE3ZK00q 
Further company coverage:  PHAR.AS 

 ((Reuters.Briefs@thomsonreuters.com;))